Simultaneous analysis of liposomal doxorubicin and doxorubicin using capillary electrophoresis and laser induced fluorescence.
A method based on a capillary electrophoresis with laser induced fluorescence detection was developed and validated for simultaneous separation of doxorubicin (DOX) and liposomal encapsulated DOX. The separation was accomplished using a fused silica capillary (60cm in total length, 75microm I.D.) and potassium phosphate buffer [12.5mM, pH 7.4] as the running buffer. The effect of sample preparation conditions on maintaining liposomal integrity was also investigated. The limit of detection for DOX was 0.1microg/ml and the precision and accuracy of CE/LIF method was within the ranges of FDA guidelines. The validated method was successfully used to quantify DOX in human plasma using a direct injection of a 4-fold dilution of spiked liposomal DOX in human plasma.
Kim
Hee Seung
HS
Gerontology Research Center, National Institute on Aging, National Institutes of Health, 5600 Nathan Shock Drive, Baltimore, MD 21224, USA. hskjay@hotmail.com
Wainer
Irving W
IW
D000903:Antibiotics, Antineoplastic / Q000032:analysis*; D002021:Buffers; D002138:Calibration; D004317:Doxorubicin / Q000032:analysis*; D004355:Drug Stability; D019075:Electrophoresis, Capillary / Q000379:methods*; D005453:Fluorescence; D005615:Freezing; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007834:Lasers; D057230:Limit of Detection; D011786:Quality Control; D012015:Reference Standards; D015203:Reproducibility of Results; D013997:Time Factors
D000903:Antibiotics, Antineoplastic; D002021:Buffers; D004317:Doxorubicin